STAT Plus: Private insurance might provide some shield from insulin price hikes — but the picture of costs is complicated
Although the cost of insulin has risen dramatically over the years and prompted a political…
Category: Pharma
STAT Plus: Pharmalittle: FDA used ‘threadbare evidence’ to OK malaria drugs; GAO slams FDA’s supply-chain oversight, again
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: Pharmalittle: Stressed Americans cause a shortage of an antidepressant; Dems attack GOP candidates over malaria drug
Rise and shine, another busy day is on the way. And it feels particularly busy….
STAT Plus: Despite protest, industry group backs use of horseshoe crab blood to test for bacteria in drugs
After a lengthy review, the organization that sets manufacturing standards for drug makers will keep…
STAT Plus: Pharmalittle: Fauci ‘didn’t like’ Moderna vaccine data release; Pfizer breast cancer drug suffers a setback
Good morning, everyone, and welcome to another working week. We hope the weekend respite, if…
The WHO launched a voluntary Covid-19 product pool. What happens next?
After weeks of planning, the World Health Organization formally launched a voluntary pool to collect…
.jpg)
STAT Plus: Pharmalittle: Administration mishandled initial remdesivir distribution; AstraZeneca lung cancer drug shows big benefit
And so, another working week will soon draw to a close. Not a moment, too…
Pharma leaders shoot down WHO voluntary pool for patent rights on Covid-19 products
The heads of some of the world’s largest drug makers expressed a mix of confusion…
STAT Plus: Pharmalittle: Glaxo aims for 1 billion doses of a Covid-19 vaccine booster; Pence aide holds lots of pharma stocks
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: FDA finds ‘unacceptable’ levels of a possible carcinogen in a widely used diabetes pill
After months of testing, the Food and Drug Administration reported finding unacceptable levels of a…
STAT Plus: Medical societies have ‘extensive’ financial ties with drug and device makers
Many leaders of influential medical societies have extensive financial relationships with drug and device makers,…
STAT Plus: Vertex angers U.K. cystic fibrosis patients with a delay in submitting data for its newest therapy
Vertex Pharmaceuticals (VRTX) has sparked a new round of anger among cystic fibrosis patients in…
STAT Plus: Pharmalittle: Moderna executives cashed out big time; should we have ‘quality scores’ for manufacturing drugs?
Hello, everyone, and how are you today? We are coping so far, thank you. Despite…
STAT Plus: Experts push for a ‘seal of approval’ to improve the quality of medicines
Should there be a Good Housekeeping ‘seal of approval’ for prescription medicines? In a new…
STAT Plus: A pharma effort to work with European officials to develop new drugs is a “failure”
In a scathing report, a pair of non-governmental organizations accused the European pharmaceutical industry of…
STAT Plus: Pharmalittle: Merck enters Covid-19 vaccine race; pharma alarmed by push for U.S.-only supply chain
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: ‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi
Peter Adamson joined Sanofi in late March, as the coronavirus pandemic surged around the world…
First generic version of Gilead’s remdesivir will be sold by a Bangladesh drug maker
A drug maker in Bangladesh has become the first company to sell a generic version…
STAT Plus: Phlow CEO speaks out on criticism of his record, plans for a drug ingredient stockpile, and a huge government contract
Earlier this week, the U.S. government awarded a $354 million contract to a new public…
STAT Plus: Pharmalittle: Coronavirus vaccine may not be a cure-all; hydroxychloroquine fails in a Covid-19 study
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: In a tale of two Mercks, the German company wins a court battle over its U.S. rival
In a setback for Merck (MRK), a court in London ruled that the big drug…
STAT Plus: After years of manufacturing problems, Akorn files for bankruptcy protection
After mounting financial and manufacturing woes, Akorn (AKRX) has filed for bankruptcy protection, a humbling…
.jpg)
U.S. gives up to $1.2 billion to AstraZeneca for Covid-19 vaccine
The race over funding and access to a Covid-19 vaccine is heating up as the…
STAT Plus: Pharmalittle: Trump’s Covid-19 vaccine chief has worrisome conflicts; U.S. provides $1.2 billion for AstraZeneca vaccine
Top of the morning to you, and a fine one it is. Once again, clear…
STAT Plus: Biosimilars got the cold shoulder from health plans when it came to preferred coverage
As debate rages over adoption of biosimilars in the U.S., a new analysis finds that…
STAT Plus: Pharmalittle: Experts say wait-and-see about Moderna’s Covid-19 vaccine; J&J will stop selling talc products in the U.S.
Hello, everyone, and welcome to the middle of the week. Time flies when you are…
CEO tapped by Trump to make generic drugs during pandemic has a dicey track record
As the chief executive of Phylo, the new company awarded $354 million by the federal government…
STAT Plus: Pharmalittle: White House signs deal for U.S.-made generics to fight Covid-19; Gilead expands remdesivir donations
Rise and shine, another brand new day is here. Thanks to a sunny sky and…
STAT Plus: Despite skepticism, Gilead’s remdesivir could become a ‘multi-year commercial opportunity’
As speculation mounts over pricing for remdesivir, a Gilead Sciences (GILD) executive suggested the experimental…
EMA urged to release full clinical trial data upon authorizing Covid-19 treatments
Amid a worldwide clamor for Covid-19 medicines and vaccines, the European Medicines Agency is being…
STAT Plus: Pharmalittle: U.K. will get first access to an AstraZeneca Covid-19 vaccine; VA will continue using old malaria drug
Good morning, everyone, and welcome to another working week. We hope the weekend interlude was…
WHO embraces plan for Covid-19 intellectual property pool
In response to the global race to combat the Covid-19 pandemic, the World Health Organization…
STAT Plus: Pharmalittle: France piles pressure on Sanofi over Covid-19 vaccine; GOP fails to land a punch on Bright
And so, another working week will soon draw to a close. Not a moment too…
Less than a movie ticket or ‘impossible to overpay’? Experts name their price for remdesivir
Two weeks ago, the world learned that remdesivir, a treatment from Gilead Sciences, has a…
STAT Plus: Many pivotal drug studies don’t include data on race or ethnicity, analysis finds
Amid concerns that clinical trials do not adequately represent patient populations, a new analysis finds…
STAT Plus: Pharmalittle: Sanofi walks back Covid-19 vaccine remarks; Trump to name vaccine czar with conflicts
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
CVS long-term care pharmacy pays $15 million penalty for failing to track opioids
Omnicare, which is the largest long-term care pharmacy in the U.S., agreed to pay a…
STAT Plus: Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study
Roche on Wednesday said a two-drug combination that includes a novel but still experimental checkpoint-blocking…
World Health Assembly draft resolution boosts access to Covid-19 medicines
World Health Assembly negotiators have agreed on a draft resolution that ensures countries can navigate…
Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results
When Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, described the results…
STAT Plus: Pharmalittle: FDA rejects drug from Bristol and Bluebird; Gilead signs deals to widen access to remdesivir
Rise and shine, everyone, another busy day is on the way. Although the days may…
Gilead signs licenses for generic companies to make and sell remdesivir in 127 countries
Seeking to blunt concerns about access to its remdesivir treatment for Covid-19, Gilead Sciences (GILD)…
STAT Plus: Pharmalittle: Birx acknowledges remdesivir distribution was flawed; Moderna gets FDA fast track for Covid-19 vaccine
Top of the morning to you, and a fine one it is. Despite the doom…
STAT Plus: Pharmalittle: Hackers linked to Iran sought Gilead Covid-19 data; NIH to test remdesivir with a Lilly drug
Hello, everyone, and welcome to another working week. We hope the weekend respite was sufficiently…
STAT Plus: A new Trump administration rule could increase out-of-pocket drug costs
Even as prescription drug costs remain an important pocketbook issue for many Americans, the Trump…
STAT Plus: Pharmalittle: Hydroxycholoroquine fails to help patients in a study; what will states do with the old malaria drug now?
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Maryland governor vetoes funding for a prescription drug affordability board
In a surprise move, Maryland Gov. Larry Hogan vetoed state funding for a “Prescription Drug…
The U.S. government contributed research to a Gilead remdesivir patent — but didn’t get credit
Two documents dating back to 2015 shed further light on the role the federal government…
STAT Plus: Apotex to pay $24 million to settle price fixing charges stemming from long-running probe
In the latest fallout from a federal probe into generic drug price fixing, Apotex agreed…
STAT Plus: Pharmalittle: Hospitals criticize feds over remdesivir supplies; Moderna starting mid-stage Covid-19 vaccine trials soon
Hello, everyone, and how are you today? We are doing just fine, thank you, given…